Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer
Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer
复制标题
DOI：
10.1097/01.cad.0000217425.44584.9f
复制
发表时间：
2006-08-01
影响因子：
2.3
通讯作者：
Pruvot, Francois-Rene
中科院分区：
文献类型：
--
作者：
Hebbar, Mohamed;Wacrenier, Agnes;Pruvot, Francois-Rene
在转移性结直肠癌患者中，使用西妥昔单抗目前需要记录肿瘤表皮生长因子受体阳性。然而，对西妥昔单抗的反应在表皮生长因子受体阴性肿瘤患者中已有报道。我们在所有符合条件的转移性结直肠癌患者中使用了西妥昔单抗，无论其肿瘤是否表达表皮生长因子受体。我们评估了西妥昔单抗在肿瘤表皮生长因子受体表达方面的疗效。20例转移性结直肠癌患者在奥沙利铂和伊立替康方案失败后退出研究，接受西妥昔单抗和伊立替康治疗。通过免疫组化分析所有患者的肿瘤表皮生长因子受体表达。肿瘤表皮生长因子受体阳性12例，阴性8例。在4例患者（20%）中获得了对基于西妥昔单抗的治疗的客观应答。这4例患者的肿瘤表皮生长因子受体表达阴性。这些结果进一步证明了在转移性结直肠癌患者中，通过免疫组化检测表皮生长因子受体对西妥昔单抗治疗无效。
In patients with metastatic colorectal cancer, the use of cetuximab currently requires a documented tumoral epidermal growth factor receptor positivity. Responses to cetuximab, however, have been described in patients with epidermal growth factor receptor-negative tumors. We have used cetuximab in all eligible patients with metastatic colorectal cancer, whether their tumor expressed epidermal growth factor receptor or not. We assessed the cetuximab efficacy with regard to tumoral epidermal growth factor receptor expression. Twenty patients with metastatic colorectal cancer were treated off study with cetuximab and irinotecan after failure of oxaliplatin- and irinotecan-based regimens. Tumors were analyzed in all patients for epidermal growth factor receptor expression by immunohistochemistry. Tumors were positive for epidermal growth factor receptor in 12 cases and negative in eight cases. An objective response to cetuximab-based therapy was obtained in four patients (20%). Tumors of these four patients were negative for epidermal growth factor receptor expression. These results provide further evidence for the lack of usefulness of epidermal growth factor receptor detection by immunohistochemistry for cetuximab therapy in patients with metastatic colorectal cancer.